Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Xu, Kai Yu ^a   Xia, Geng Hong ^a   Lu, Jun Qi ^a,b   Chen, Mu Xuan ^b   Zhen, Xin ^a   Wang, Shan ^b   You, Chao ^a   Nie, Jing ^a   Zhou, Hong Wei ^b   Yin, Jia ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETAINE; CARNITINE; CHOLINE; METHYLAMINE; TRIMETHYLOXAMINE;

ADULT; AGED; ANIMAL; BLOOD; C57BL MOUSE; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; CLASSIFICATION; CLOSTRIDIACEAE; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; GAMMAPROTEOBACTERIA; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; INTESTINE FLORA; KIDNEY FUNCTION TEST; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MOUSE; PATHOLOGY;

ADULT; AGED; ANIMALS; BETAINE; CARNITINE; CASE-CONTROL STUDIES; CHOLINE; CLOSTRIDIACEAE; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; GAMMAPROTEOBACTERIA; GASTROINTESTINAL MICROBIOME; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KIDNEY FUNCTION TESTS; MALE; METHYLAMINES; MICE; MICE, INBRED C57BL; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 85018774237     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-01387-y     Document Type: Article

References (54)

1. Eckardt, K. U., et al. Evolving importance of kidney disease: From subspecialty to global health burden. Lancet 382, 158-69, doi:10.1016/S0140-6736(13)60439-0 (2013).
2. Liu, M., et al. Cardiovascular disease and its relationship with chronic kidney disease. Eur Rev Med Pharmacol Sci 18, 2918-26 (2014).
3. Segall, L., Nistor, I., Covic, A. Heart failure in patients with chronic kidney disease: A systematic integrative review. Biomed Res Int 2014, 937398-21, doi:10.1155/2014/937398 (2014).
4. Hou, F. F. Cardiovascular risk in Chinese patients with chronic kidney diseases: Where do we stand Chin Med J (Engl) 118, 883-6 (2005).
5. Alani, H., Tamimi, A., Tamimi, N. Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. World J Nephrol 3, 156-68, doi:10.5527/wjn.v3.i4.156 (2014).
6. Gansevoort, R. T., et al. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, prevention. Lancet 382, 339-52, doi:10.1016/S0140-6736(13)60595-4 (2013).
7. Ridaura, V. K., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214-1241214, doi:10.1126/science.1241214 (2013).
8. Qin, J., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55-60, doi:10.1038/nature11450 (2012).
9. Abu-Shanab, A., Quigley, E. M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7, 691-701, doi:10.1038/nrgastro.2010.172 (2010).
10. Vaziri, N. D., et al. Chronic kidney disease alters intestinal microbial flora. Kidney Int 83, 308-315, doi:10.1038/ki.2012.345 (2013).
11. Andersen, K., et al. Intestinal Dysbiosis, Barrier Dysfunction, Bacterial Translocation Account for CKD-Related Systemic Inflammation. J Am Soc Nephrol (2016).
12. Tang, W. H., et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 368, 1575-84, doi:10.1056/NEJMoa1109400 (2013).
13. Tang, W. H., et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, adverse clinical outcomes in chronic systolic heart failure. J Card Fail 21, 91-96, doi:10.1016/j.cardfail.2014.11.006 (2015).
14. Koeth, R. A., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19, 576-85, doi:10.1038/nm.3145 (2013).
15. Tang, W. H., et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 116, 448-55, doi:10.1161/CIRCRESAHA.116.305360 (2015).
16. Kim, R. B., et al. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. Kidney Int 89, 1144-52, doi:10.1016/j.kint.2016.01.014 (2016).
17. Yin, J., et al. Dysbiosis of Gut Microbiota With Reduced Trimethylamine-N-Oxide Level in Patients With Large-Artery Atherosclerotic Stroke or Transient Ischemic Attack. J Am Heart Assoc 4, doi:10.1161/JAHA.115.002699 (2015).
18. Senthong, V., et al. Intestinal Microbiota-Generated Metabolite Trimethylamine-N-Oxide and 5-Year Mortality Risk in Stable Coronary Artery Disease: The Contributory Role of Intestinal Microbiota in a COURAGE-Like Patient Cohort. J Am Heart Assoc 5, e002816, doi:10.1161/JAHA.115.002816 (2016).
19. Lozupone, C., Lladser, M. E., Knights, D., Stombaugh, J., Knight, R. UniFrac: An effective distance metric for microbial community comparison. Isme J 5, 169-72, doi:10.1038/ismej.2010.133 (2011).
20. Langille, M. G., et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 31, 814-821, doi:10.1038/nbt.2676 (2013).
21. Goodrich, J. K., et al. Conducting a microbiome study. Cell 158, 250-62, doi:10.1016/j.cell.2014.06.037 (2014).
22. Missailidis, C., et al. Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease. Plos One 11, e141738, doi:10.1371/journal.pone.0141738 (2016).
23. Bennett, B. J., et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 17, 49-60, doi:10.1016/j.cmet.2012.12.011 (2013).
24. Stubbs, J. R., et al. Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. J Am Soc Nephrol 27, 305-313, doi:10.1681/ASN.2014111063 (2016).
25. Rhee, E. P., et al. A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol 24, 1330-8, doi:10.1681/ASN.2012101006 (2013).
26. Kato, L. M., Kawamoto, S., Maruya, M., Fagarasan, S. The role of the adaptive immune system in regulation of gut microbiota. Immunol Rev 260, 67-75, doi:10.1111/imr.2014.260.issue-1 (2014).
27. Zhu, Y., et al. Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc Natl Acad Sci USA 111, 4268-73, doi:10.1073/pnas.1316569111 (2014).
28. den Besten, G., et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, host energy metabolism. J Lipid Res 54, 2325-40, doi:10.1194/jlr.R036012 (2013).
29. Peng, L., Li, Z. R., Green, R. S., Holzman, I. R., Lin, J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139, 1619-25, doi:10.3945/jn.109.104638 (2009).
30. Keku, T. O., Dulal, S., Deveaux, A., Jovov, B., Han, X. The gastrointestinal microbiota and colorectal cancer. Am J Physiol Gastrointest Liver Physiol 308, G351-G363, doi:10.1152/ajpgi.00360.2012 (2015).
31. Rios-Covian, D., et al. Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health. Front Microbiol 7, 185, doi:10.3389/fmicb.2016.00185 (2016).
32. Wong, J., et al. Expansion of urease-A nd uricase-containing, indole-A nd p-cresol-forming and contraction of short-chain fatty acidproducing intestinal microbiota in ESRD. Am J Nephrol 39, 230-7, doi:10.1159/000360010 (2014).
33. Shin, N., Whon, T. W., Bae, J. Proteobacteria: Microbial signature of dysbiosis in gut microbiota. Trends Biotechnol 33, 496-503, doi:10.1016/j.tibtech.2015.06.011 (2015).
34. Lupp, C., et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2, 119-29, doi:10.1016/j.chom.2007.06.010 (2007).
35. Poza, M., et al. Exploring bacterial diversity in hospital environments by GS-FLX Titanium pyrosequencing. Plos One 7, e44105, doi:10.1371/journal.pone.0044105 (2012).
36. Masood, M. I., Qadir, M. I., Shirazi, J. H., Khan, I. U. Beneficial effects of lactic acid bacteria on human beings. Crit Rev Microbiol 37, 91-98, doi:10.3109/1040841X.2010.536522 (2011).
37. Falony, G., et al. Population-level analysis of gut microbiome variation. Science 352, 560-564, doi:10.1126/science.aad3503 (2016).
38. Sorensen, L. B. Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum 8, 694-706, doi:10.1002/(ISSN)1529-0131 (1965).
39. Poesen, R., et al. The Influence of CKD on Colonic Microbial Metabolism. J Am Soc Nephrol 27, 1389-99, doi:10.1681/ASN.2015030279 (2016).
40. Takayama, F., Taki, K., Niwa, T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis 41, S142-S145, doi:10.1053/ajkd.2003.50104 (2003).
41. Ranganathan, N., et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther 27, 634-647, doi:10.1007/s12325-010-0059-9 (2010).
42. Chapter 2: Definition, identification, prediction of CKD progression. Kidney Int Suppl (2011) 3 63 (2013).
43. Cooper, B. A., et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363, 609-619, doi:10.1056/NEJMoa1000552 (2010).
44. Peng, X., et al. Comparison of direct boiling method with commercial kits for extracting fecal microbiome DNA by Illumina sequencing of 16S rRNA tags. J Microbiol Methods 95, 455-62, doi:10.1016/j.mimet.2013.07.015 (2013).
45. Zhou, H. W., et al. BIPES, a cost-effective high-throughput method for assessing microbial diversity. Isme J 5, 741-9, doi:10.1038/ismej.2010.160 (2011).
46. Caporaso, J. G., et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7, 335-6, doi:10.1038/nmeth.f.303 (2010).
47. Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460-2461, doi:10.1093/bioinformatics/btq461 (2010).
48. Caporaso, J. G., et al. PyNAST: A flexible tool for aligning sequences to a template alignment. Bioinformatics 26, 266-7, doi:10.1093/bioinformatics/btp636 (2010).
49. Price, M. N., Dehal, P. S., Arkin, A. P. FastTree: Computing large minimum evolution trees with profiles instead of a distance matrix. Mol Biol Evol 26, 1641-50, doi:10.1093/molbev/msp077 (2009).
50. McDonald, D., et al. The Biological Observation Matrix (BIOM) format or: How I learned to stop worrying and love the ome-ome. Gigascience 1, 7, doi:10.1186/2047-217X-1-7 (2012).
51. Segata, N., et al. Metagenomic biomarker discovery and explanation. Genome Biol 12, R60, doi:10.1186/gb-2011-12-6-r60 (2011).
52. Wang, Z., et al. Measurement of trimethylamine-N-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry. Anal biochem 455, 35-40, doi:10.1016/j.ab.2014.03.016 (2014).
53. Gregory, J. C., et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem 290, 5647-60, doi:10.1074/jbc.M114.618249 (2015).
54. Langille, M. G., et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 31, 814-821, doi:10.1038/nbt.2676 (2013).